Medivation touts Phase II data on Huntington's therapy

Shares of Medivation surged--briefly--after the company announced mid-stage data on Dimebon showing that Huntington's patients taking a three-month course of the drug demonstrated improved cognitive function compared to a placebo group. The Dimebon group suffered fewer falls on average than the placebo group. Researchers also noted an improvement for patients based on the United Huntington's Disease Rating Scale--but the results were not statistically significant. Shares jumped 22 percent but quickly slid back to a two percent gain, according to TheStreet. The CEO of Medivation says that the company will prepare for a Phase III trial.

"To my knowledge, no other drug has resulted in statistically significant benefit in cognition in Huntington's disease patients in a randomized, well-controlled trial," said Karl Kieburtz, M.D., M.P.H., the principal investigator. "Cognitive impairment is the most important therapeutic unmet need in Huntington's disease. I am pleased by this result and Dimebon's favorable safety profile, and believe that further development of this compound is warranted."

- check out Medivation's release
- read the report from TheStreet

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.